AQEMIA Enters into a Multi-Year Research Collaboration with Sanofi
- Under the agreement, AQEMIA will employ its generative AI and deep physics algorithms to design molecules, conducting in-house physics-based calculations efficiently while Sanofi will utilize its global R&D expertise to expedite the development of therapeutic drugs addressing unmet needs
- The aim of the collaboration covers the entire drug discovery process, from initial hits to the development of selected candidates through AQEMIA's platform that will pinpoint the appropriate chemical molecules for Sanofi's therapeutic targets
- AQEMIA stands to receive up to $140M, comprising an up front payment and milestone achievements in R&D for specific therapeutic targets. Sanofi will only be responsible for wet lab research, development, and commercialization activities
Ref: Businesswire | Image: Sanofi
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at firstname.lastname@example.org.